Andrew J. Thompson

Andrew J. Thompson

Auto-generated profile, based on publicly available information

Andrew J. Thompson

Department of Pharmacology, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Neuropharmacology
Verified
Journal Article
Open access
Martin LochnerMartin Lochner
Martin Lochner
ATAndrew J. Thompson
Andrew J. Thompson
Scopolamine is a high affinity muscarinic antagonist that is used for the prevention of post-operative nausea and vomiting. 5-HT3 receptor antagonists are used for the same purpose and are structurally related to scopolamine. To examine whether 5-HT3 receptors are affected by scopolamine we examined the effects of this drug on the electrophysiological and ligand binding properties of 5-HT3A receptors expressed in Xenopus oocytes and HEK293 cells, respectively. 5-HT3 receptor-responses were reversibly inhibited by scopolamine with an IC50 of 2.09 μM. Competitive antagonism was shown by Schild plot (pA2 = 5.02) and by competition with the 5-HT3 receptor antagonists [(3)H]granisetron (Ki = 6.76 μM) and G-FL (Ki = 4.90 μM). The related molecule, atropine, similarly inhibited 5-HT evoked responses in oocytes with an IC50 of 1.74 μM, and competed with G-FL with a Ki of 7.94 μM. The reverse experiment revealed that granisetron also competitively bound to muscarinic receptors (Ki = 6.5 μM). In behavioural studies scopolamine is used to block muscarinic receptors and induce a cognitive deficit, and centrally administered concentrations can exceed the IC50 values found here. It is therefore possible that 5-HT3 receptors are also inhibited. Studies that utilise higher concentrations of scopolamine should be mindful of these potential off-target effects.

1 February 2013 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
ATAndrew J. Thompson
Andrew J. Thompson

12 March 2013 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
ATAj Thompson
Aj Thompson
SLScr Lummis
Scr Lummis
The5‐HT3Bsubunit was first cloned in 1999, and co‐expression with the5‐HT3Asubunit results in heteromeric5‐HT3ABreceptors that are functionally distinct from homomeric5‐HT3Areceptors. The affinities of competitive ligands at the two receptor subtypes are usually similar, but those of non‐competitive antagonists that bind in the pore often differ. A competitive ligand and allosteric modulator that distinguishes5‐HT3Afrom5‐HT3ABreceptors has recently been described, and the number of non‐competitive antagonists identified with this ability has increased in recent years. In this review, we discuss the differences between5‐HT3Aand5‐HT3ABreceptors and describe the possible sites of action of compounds that can distinguish between them.

1 June 2017 in Neuropharmacology
Verified
Journal Article
Open access
MRMarc-David Ruepp
Marc-David Ruepp
HWHao Wei
Hao Wei
MLMichele Leuenberger
Michele Leuenberger
Martin LochnerMartin Lochner
Martin Lochner
ATAndrew J. Thompson
Andrew J. Thompson
Crystal structures can identify ligand-receptor interactions and assist the development of novel therapeutics, but experimental challenges sometimes necessitate the use of homologous proteins. Tropisetron is an orthosteric ligand at both 5-HT3 and α7 nACh receptors and its binding orientation has been determined in the structural homologue AChBP (pdbid: 2WNC). Co-crystallisation with a structurally-related ligand, granisetron, reveals an almost identical orientation (pdbid; 2YME). However, there is a >1000-fold difference in the affinity of tropisetron at 5-HT3 versus α7 nACh receptors, and α7 nACh receptors do not bind granisetron. These striking pharmacological differences prompt questions about which receptor the crystal structures most closely represent and whether the ligand orientations are correct. Here we probe the binding orientation of tropisetron and granisetron at 5-HT3 receptors by in silico modelling and docking, radioligand binding on cysteine-substituted 5-HT3 receptor mutants transiently expressed in HEK 293 cells, and synthetic modification of the ligands. For 15 of the 23 cysteine substitutions, the effects on tropisetron and granisetron were different. Structure-activity relationships on synthesised derivatives of both ligands were also consistent with different orientations, revealing that contrary to the crystallographic evidence from AChBP, the two ligands adopt different orientations in the 5-HT3 receptor binding site. Our results show that even quite structurally similar molecules can adopt different orientations in the same binding site, and that caution may be needed when using homologous proteins to predict ligand binding.

1 March 2015 in Neuropharmacology
Verified
Journal Article
Closed access
TJThomas Jack
Thomas Jack
JSJonathan Simonin
Jonathan Simonin
MRMarc-David Ruepp
Marc-David Ruepp
ATAndrew J. Thompson
Andrew J. Thompson
Jürg GertschJürg Gertsch
Jürg Gertsch
Martin LochnerMartin Lochner
Martin Lochner

20 October 2009 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
ATAj Thompson
Aj Thompson
PMPk Mander
Pk Mander
GBGc Brown
Gc Brown
Background and purpose: It has been previously shown that high levels of nitric oxide (NO), from NO donors, kill neurones, but the mechanisms are unclear. Experimental approach: The effects of NO donors on the electrical properties of rat cultured cerebellar granule cells (CGC neurones) were investigated using the whole‐cell patch‐clamp technique. Key results: The NO donor (Z)‐1‐[2‐(2‐aminoethyl)‐N‐(2‐ammonioethyl)amino]diazen‐1‐ium‐1,2‐diolate (DETA‐NONOate or NOC‐18) caused a rapid, persistent, but fully reversible inward current that was associated with an increase in baseline noise and was concentration dependent (100 µM–10 mM). The response to 3 mM DETA‐NONOate was completely inhibited by 1 mM gadolinium, but not by NO scavengers (1 mM haemoglobin or 1 mM PTIO) or glutamate receptor antagonists (10 µM MK‐801 or 60 µM CNQX). Application of decomposed 3 mM DETA‐NONOate or 3 mM nitrite had no effect. In contrast, the NO donor S‐nitrosoglutathione (GSNO) caused a rapid, persistent, but fully reversible outward current that was also concentration dependent (1–10 mM). The 3 mM GSNO response was unaltered by NO scavengers, glutamate antagonists or gadolinium, but was mimicked by decomposed 3 mM GSNO and 3 mM oxidized glutathione. Conclusions and implications: These results suggest that DETA‐NONOate directly activates cation‐selective channels, causing an inward current in CGCs. In contrast, GSNO causes an outward current in these cells. Some of the effects of these NO donors are independent of NO, and thus caution is required in interpreting results when using high concentrations of these compounds.